RxDoctor Payments Data

Jonathan Powell

Medical Oncology · Baltimore, MDNPI 1629011432

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,500 of the $11,162 with a category attached, or 94.1%. 6 manufacturers reported payments, led by AstraZeneca at 56.1% of the total. Reporting peaked in 2019 at $7,079 and has fallen 98.8% since, to $83 in 2024.

$11,162in general payments, 2019–2025

Across 16 payments — averaging $697.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Shionogi Inc$4K
  • Vertex$500
  • Astrazeneca AB$266
  • AbbVie$83
  • E.r. Squibb & Sons, L.L.C.$52
$1,265,535in research payments, 2019–2025

Across 4 payments — averaging $316,384 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$1.3M

What the payments were for

  • Consulting fees$10,50094%
  • Travel & lodging$3123%
  • Food & beverage$3503%

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca7$6,261
Shionogi Inc1$4,000
Vertex1$500
Astrazeneca AB5$266
AbbVie1$83
E.r. Squibb & Sons, L.L.C.1$52

How this compares

$11,162 in reported general payments places this provider in the 60th percentile of 180 medical oncology providers in Maryland.

See all medical oncology providers in Maryland

Other medical oncology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →